Balaji Amines Limited (BALAMINES) announced its unaudited financial results for the quarter and half year ended September 30th, 2026. The consolidated revenue for Q2 FY27 stood at ₹472 crore, up from ₹348 crore in Q2 FY26. The EBITDA was ₹106 crore compared to ₹67 crore in the same quarter last year. Net profit for the quarter was ₹67 crore, significantly higher than the ₹37 crore reported in Q2 FY26.

Financial Performance

The company’s total revenue for Q2 FY27 was ₹472 crore, a notable increase from ₹348 crore in Q2 FY26. The EBITDA margin stood at 22%, down from 26% in Q1 FY27 but up from 19% in Q2 FY26. The profit after tax (PAT) for the quarter was ₹67 crore, up from ₹37 crore in the previous year’s quarter. Diluted earnings per share (EPS) for Q2 FY27 stood at ₹20.76 per equity share, compared to ₹10.67 in Q2 FY26.

Growth Drivers

The company continues to strengthen its growth platform through capacity expansion and a focus on value-added specialty chemicals. Commercial production has commenced at the expanded Acetonitrile (ACN) facility, increasing installed capacity to 1,440 TPM. The upgraded plant incorporates advanced technology and enhanced process efficiencies, positioning the company to improve operational performance over the medium term.

The successful commissioning of the 100,000 TPA Dimethyl Ether (DME) plant, India’s first commercial-scale DME facility, has established the company in a high-potential import substitution market with applications spanning healthcare, personal care products, and fuel applications. The next phase of work is in the pipeline to establish a robust network of customers as the company has already studied the ever-expanding Aerosol market. Opportunities for export of DME are explored regularly.

The next product planned for commercialization is N-Methyl Morpholine (NMM), further expanding the specialty chemicals portfolio. In parallel, Balaji Speciality Chemicals is progressing with its expansion program that is aimed at increasing the share of high-value specialty chemicals. The Unit-I brownfield expansion, comprising EDA derivatives such as DETA, TETA, Piperazine, AEEA, and AEP, remains on track for commissioning during the end of FY27. The Unit-II greenfield project at MIDC, Chincholi, which will manufacture HCN, NaCN, EDTA, and EDTA-2Na, is targeted for commissioning in Q4 FY27.

On the performance, Mr. D. Ram Reddy, Managing Director, commented, ‘Q2 FY27 reflected resilient execution and steady progress on our strategic priorities. As we enter H2 FY27, our focus is firmly on driving higher utilization, improving operating efficiencies and translating recent investments into stronger earnings growth. The commissioning of the upgraded Acetonitrile (ACN) facility and the DME plant marks an important step in expanding our presence in value-added and import-substitution products. We are now focused on scaling these capacities and unlocking their full commercial potential. We have also improved the process of Di Isopropylamine (DIPA) as continuous efforts yielded this success. Overall, the volumes have dented due to various external factors, however, the company has leveraged its strength in stabilising the product portfolio to keep the top line stable and continuing the efforts to strengthen the bottom line. Our growth pipeline remains robust, with N-Methyl Morpholine (NMM) and multiple specialty chemical projects progressing as planned. These investments will further strengthen our specialty chemicals portfolio, enhance integration and expand our participation in high-growth end markets. With a stronger product mix, a visible expansion roadmap and a disciplined focus on execution, we remain confident in our ability to drive sustainable growth, improve earnings quality and create long-term value for shareholders.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Balaji Amines Limited

Balaji Amines Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Balaji falls 9.7% over three months and has not found a floor yet. Revenue contracts at -15.6% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 66% of its 52-week range with RSI at 45. In other words, neither side has a clear edge right now. The stock holds up despite -15.6% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Balaji Amines Limited.

MOIL Limited (MOIL) has achieved remarkable growth in the first half of FY ’27, with a notable 22.5% surge in net profit. The company’s board approved the financial and operational results for the second quarter and half year of FY 27, showcasing growth across production, sales, and profitability. The board also declared a first interim dividend of Rs. 2.20 per equity share of Rs. 10 each for FY 27.

Financial Highlights

Key financial highlights for the first half of FY 2026-27 compared to FY 2025-26 include:

• Revenue from Operations: Increased by 8.7%
• Total Revenue: Increased by 5.81%
• Profit Before Tax (PBT): Registered a 22.9% growth
• Profit After Tax (PAT): Registered a growth of 22.5%

Operational Highlights

Operational highlights for the first half of FY 2026-27 compared to FY 2025-26:

• Manganese Ore Sales: Increase of 9.67%
• Manganese Ore Production: Increase of 1.76%

Appreciating the efforts of the entire MOIL team, Shri V Suresh, Chairman and Managing Director, MOIL said: “Our strong H1 performance underlines the potential of our human resource, whose hard work remains the bedrock of our success. Through incisive strategic planning and optimized mining practices, we have successfully unlocked new efficiencies. We are heavily prioritizing our ‘Waste to Wealth’ interventions to turn low grade mining products into high-value assets, ensuring sustainable growth while firmly maintaining our market price leadership to support the domestic steel ecosystem.”

Further, he assured all stakeholders that “MOIL Limited is focused on exploring new growth opportunities, both in domestic and international, across mining and downstream value addition.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of MOIL Limited

MOIL Limited belongs to the Basic Materials › Other Industrial Metals & Mining sector. Here’s a quick read on where the business and the stock stand today.

MOIL falls 13.4% over three months and has not found a floor yet. The PEG stands at 7.14 — severely stretched. Any earnings miss could trigger a sharp de-rating. D/E of 0.00 and a 6.07% dividend yield give the balance sheet a decent cushion. The stock sits at 3% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 3.2% CAGR — a respectable pace. However, the stock drops 13.4% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of MOIL Limited.

Indogulf Cropsciences Limited (NSE: IGCL | BSE: 544432) announced its consolidated unaudited financial results for the quarter and half year ended September 30, 2026, showcasing robust performance. The company’s EBITDA rose 27% year-on-year to ₹41 crore, while PAT increased by 24% to ₹26 crore. The EBITDA margin expanded by 300 basis points to 16%, reflecting disciplined cost management and a favorable product mix.

Financial Performance Snapshot

The company’s total income for Q2 FY27 stood at ₹256 crore, up 3% year-on-year. Despite weak monsoon conditions, the sequential revenue growth was 52% QoQ, indicating improved business momentum. The PAT margin improved to 10% from 8% due to lower finance costs and enhanced operating efficiencies.

Half-Year Performance

For H1 FY27, revenue from operations was ₹424 crore, showing a marginal decline of 3% YoY. However, gross profit increased by 7% to ₹123 crore, with the gross margin improving to 29%. EBITDA grew 20% to ₹50 crore, and the EBITDA margin expanded to 12%. The PAT increased 14% to ₹28 crore, with the PAT margin improving to 7%.

Looking Ahead

Commenting on the performance, Mr. Sanjay Aggarwal, Managing Director, Indogulf Cropsciences Limited, said: “We are pleased with our strong performance in Q2 FY27. The first half has seen similar progress, and we are entering the second half with strong business momentum. The national focus on raising farm productivity and farmer incomes, growing adoption of modern crop protection and crop nutrition, and the accelerating shift towards sustainable and biological solutions are creating strong tailwinds for integrated players like Indogulf.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indogulf Cropsciences Limited

Indogulf Cropsciences Limited belongs to the Basic Materials › Agricultural Inputs sector. Here’s a quick read on where the business and the stock stand today.

Indogulf falls 13.7% over three months and has not found a floor yet. The PEG of 0.55 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 5.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock sits at 19% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.6% and profits at 21.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 13.7% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Indogulf Cropsciences Limited.